<DOC>
	<DOCNO>NCT01169090</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy range dose SK-0403 subject type 2 diabetes adequately control metformin alone .</brief_summary>
	<brief_title>A Study Comparing Safety , Tolerance , Efficacy Various Doses SK-0403 Versus Placebo Sitagliptin 100 mg Patients Not Well-Controlled Metformin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male female subject type 2 diabetes 18 75 year age , inclusive Screening HbA1c 7.0 % 10.0 % metformin stable subject , 6.5 % 9.0 % subject metformin 1 antidiabetic agent ( exclude thiazolidinediones , insulin , incretin therapy [ DPP4 inhibitor GLP1 analogue ] ) , 7.5 % 11.0 % subject antidiabetic medication , take metformin , stable dose 1500 mg/day maximum tolerate dose . No antidiabetic medication metformin 3 month prior randomization . Fasting plasma glucose less 270 mg/dL ( 15 mmol/L ) screening . Body mass index 20 kg/m2 45 kg/m2 inclusive screening . History type 1 diabetes . Received treatment insulin within 30 day screen visit 1 week within 3 month screen visit . Use 3 oral antidiabetic medication time screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>